Read More

Subjects In Jaguar Health’s Placebo-Controlled Pivotal Phase 3 OnTarget Trial For Prophylaxis Of Diarrhea In Adult Cancer Patients Receiving Targeted Therapy Chose To Continue On To Stage II

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on trackCancer patients at patient advocacy events voice strong support for company's focus on

JAGX

Read More

Scinai Immunotherapeutics Ltd. Announces The Publication Following Peer-Review Of An Article Titled “Nanobodies To Multiple Spike Variants And Inhalation Of Nanobody-Containing Aerosols Neutralize SARS-coV-2 In Cell Culture And Hamsters”

Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, addressing significant medical needsJERUSALEM, Dec. 11, 2023 /PRNewswire/ -- Scinai

SCNI